Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00637780 · ClinicalTrials.gov registry record · Phase 4
Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis
A Phase 4 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT00637780 is a Phase 4 study that was terminated before completion, run by Pfizer. The registered enrollment target is 2 participants.
The verdict
NCT00637780, a Phase 4 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study will characterize the steady state pharmacokinetics of sulfasalazine delayed release tablets in pediatric Juvenile Idiopathic Arthritis patients. Data from this study will fulfill the post approval commitment to the FDA.
Interventions
- DRUG Sulfasalazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-06 |
| Est. Completion | 2014-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00637780
The ClinicalTrials.gov registry entry for NCT00637780 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sulfasalazine is the first listed.
NCT00637780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00637780 about?
NCT00637780 is a clinical study titled "Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis". This study will characterize the steady state pharmacokinetics of sulfasalazine delayed release tablets in pediatric Juvenile Idiopathic Arthritis patients. Data from this study will fulfill the post approval commitment to the FDA.
What is the current status of trial NCT00637780?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2010-06. Estimated completion is 2014-01.
What interventions are being tested in trial NCT00637780?
The interventions under investigation include: Sulfasalazine (DRUG).
Who is sponsoring clinical trial NCT00637780?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.